The downgrade from Buy to Hold and the drastic reduction in the price target from $20 to $4.25 by Jones Trading is likely to negatively impact Lumos Pharma's stock price in the short term. Such a significant change in analyst rating and price target suggests a loss of confidence in the company's near-term prospects.